Prior Authorization Guideline

Size: px
Start display at page:

Download "Prior Authorization Guideline"

Transcription

1 Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT COVERAGE Table 1. Formulary status Non-Preferred Products Alimta (permetrexed) Preferred Products II. INDICATIONS A. FDA Approved Indications 1. Mesothelioma Alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. 2. Non-Small Cell Lung Cancer Alimta as a single-agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy. The effectiveness of Alimta in second-line NSCLC was based on the surrogate endpoint, response rate. There are no controlled trials demonstrating a clinical benefit, such as a favorable survival effect or improvement of disease-related symptoms. III. GUIDELINE A. Malignant Pleural Mesothelioma 1. Alimta will be approved based on all of the following criteria: a. Confirmed diagnosis of malignant pleural mesothelioma b. Disease is unresectable or patient is not a candidate for curative surgery c. Used in combination with cisplatin

2 Authorization for therapy will be issued for length of therapy B. Non-Small Cell Lung Cancer (NSCLC) 1. Alimta will be approved based on all of the following criteria: a. Confirmed diagnosis of locally advanced or metastatic (Stage III or IV) non-small cell lung cancer b. Prior history of first-line chemotherapy treatment for non-small cell lung cancer (e.g. bevacizumab, or cisplatin-based or paclitaxel chemotherapy regimens) 2 Authorization for therapy will be issued for length of therapy IV. CONTRAINDICATIONS AND WARNINGS A. Contraindications Alimta is contraindicated in patients who have a history of severe hypersensitivity reaction to pemetrexed or to any other ingredient used in the formulation. B. Warnings 1. Decreased Renal Function Alimta is primarily eliminated unchanged by renal excretion. No dosage adjustment is needed in patients with creatinine clearance Ý45 ml/min. Insufficient numbers of patients have been studied with creatinine clearance <45 ml/min to give a dose recommendation. Therefore, Alimta should not be administered to patients whose creatinine clearance is <45 ml/min. 2. Bone Marrow Suppression Alimta can suppress bone marrow function, as manifested by neutropenia, thrombocytopenia, and anemia (or pancytopenia), myelosuppression is usually the doselimiting toxicity. Dose reductions for subsequent cycles are based on nadir ANC, platelet count, and maximum nonhematologic toxicity seen in the previous cycle. 3. Need for Folate and Vitamin B 12 Supplementation Patients treated with Alimta must be instructed to take folic acid and vitamin B 12 as a prophylactic measure to reduce treatment-related hematologic and GI toxicity. In clinical studies, less overall toxicity and reductions in Grade 3/4 hematologic and nonhematologic toxicities such as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia were reported when pretreatment with folic acid and vitamin B12 was administered. 4. Pregnancy Category D Alimta may cause fetal harm when administered to a pregnant woman. Pemetrexed was fetotoxic and teratogenic in mice at i.p. doses of 0.2 mg/kg (0.6 mg/m2) or 5 mg/kg (15 mg/m2) when given on gestation days 6 through 15. Pemetrexed caused fetal malformations (incomplete ossification of talus and skull bone) at 0.2 mg/kg (about 1/833

3 the recommended i.v. human dose on a mg/m2 basis), and cleft palate at 5 mg/kg (about 1/33 the recommended i.v. human dose on a mg/m2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced litter sizes. There are no studies of Alimta in pregnant women. Patients should be advised to avoid becoming pregnant. If Alimta is used during pregnancy, or if the patient becomes pregnant while taking Alimta, the patient should be apprised of the potential hazard to the fetus. V. DOSING Alimta Mesothelioma: 500 mg/m 2 IV infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 infused over 2 hours beginning approximately 30 minutes after the end of Alimta administration. Non-Small Cell Lung Cancer: Premedication Regimen 500 mg/m 2 IV infusion over 10 minutes on Day 1 of each 21-day cycle. Dexamethasone 4 mg po twice daily the day before, the day of, and the day after Alimta administration. Folic acid 350 to 1000 mcq daily, at least 5 daily doses during the 7-days period preceding the first dose of Alimta, continued during the full course and for 21 days after the last dose of Alimta. Vitamin B mcg IM during the week preceding the first dose of Alimta and every 3 cycles thereafter. Subsqeuent Vitamin B 12 injections may be given the same day as Alimta. Dose Reduction Recommendations Dose adjustments at the start of a subsequent cycle should be based on nadir hemotologic counts or maximum nonhematologic toxicity from the preceding cycle of therapy. Treatment should be delayed to allow sufficient time for recovery. Upon recovery, patients should be retreated using the guidelines in Table 2-4. Table 2: Dose Reduction for Alimta and Cisplatin Hemotologic Toxicities Nadir ANC < 500/mm 3 and nadir 75% of previous dose (both drugs) platelets 50,000/mm 3 Nadir platelets < 50,000/mm 3 50% of previous dose (both drugs) regardless of nadir ANC. Table 3: Dose Reduction Nonhematologic Toxicities a,b Dose of Alimta Dose of Cisplatin Any Grade 3 c or 4 toxicities 75% of previous dose 75% of previous dose except mucositis Any diarrhea requiring 75% of previous dose 75% of previous dose

4 hospitalization Grade 3 or 4 mucositis 50% of previous dose 100% of previous dose a NCI Common Toxicity Criteria (CTC) b Excluding neurotoxicity Except Grade 3 transaminase elevation Table 4: Dose Reduction for Alimta and Cisplatin Neurotoxicity CTC Grade Dose of Alimta Dose of Cisplatin % of previous dose 100% of previous dose 2 100% of previous dose 50% of previous dose VI. AVAILABILITY Alimta injection is available in sterile single-use vials containing 500 mg of permetrexed. VII. BACKGROUND A. Description Alimta, permetrexed for injection, is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. B. Clinical Studies 1. Malignant Pleural Mesothelioma In a multicenter, Phase III, single-blind, randomized trial (n=456), the efficacy and toxicity of permetrexed with cisplatin was compared to cisplatin alone in patients with malignant pleural mesothelioma (MPM). The primary outcome was survival. On an intent-to-treat basis, the median survival time was significantly longer for patients treated with permetrexed and cisplatin versus cisplatin alone: 12.1 months vs. 9.3 months (logrank p=0.020). The 2.8-month survival benefit represents a hazard ratio of 0.77 or relative risk reduction for death of 23%. 2. Non-Small Cell Lung Cancer In a Phase III, randomized trial (n=571), the efficacy and toxicity of pemetrexed was compared to docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with one prior chemotherapy. 3 The primary endpoint was overall survival. On an intent-to-treat basis, the median survival time for permetrexed was 8.3 months versus 7.9 for docetaxel (HR, 0.99; 95% CI: ; noninferiority p=0.226). In incidence of Grade 3 and 4 hematologic toxicities such as neutropenia, febrile neutropenia, and neutropenia with infection was significantly less (p<0.001, <0.001, =0.004, respectively) in patients taking permetrexed compared to docetaxel. The authors concluded that treatment with permetrexed demonstrated clinically equivalent efficacy with significant improved safety profile compared with those receiving docetaxel. The authors suggest that treatment with pemetrexed should be considered standard treatment option for second-line NSCLC. C. National Guidelines 1. National Comprehensive Cancer Network 2

5 Non-Small Cell Lung Cancer For recurrent and metastatic disease, first-line therapy with bevacizumab in combination with chemotherapy is the preferred treatment option for patients with performance status (PS) of 0-2 who meet the eligibility criteria (nonsquamous cell histology, no history of hemoptysis, no CNS metastases and no ongoing therapeutic anticoagulation). In patients with who are non-candidates for bevacizumab treatment, platinum-based chemotherapy regimen is recommended as first-line chemotherapy for the treatment of advanced disease. As yet, there is no evidence that one platinum-based regimen is better than others. Docetaxel, permetrexed, and erlotinib are recommended single agent second-line chemotherapy regimens for patients with PS of 0-2 and who have experienced disease progression during or after first-line therapy. VIII. REFERENCES 1. Alimta Prescribing Information. Eli Lilly and Company, January National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology v Non-Small Cell Lung Cancer. Available at: Accessed November 16, Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: Hanna N et al. Randomized phase III trial of permetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: This Prior Authorization Guideline represents the recommendation of Prescription Solutions Pharmacy and Therapeutics (P&T) Committee. It is based upon the P&T Committee s review of the available evidence as of the date of drafting or revision of this Prior Authorization Guideline. It is subject to updating from time to time, based upon changes in scientific knowledge and information. This Prior Authorization Guideline is intended as a resource for making coverage decisions for Health Plan members, but it does not replace an individualized case-by-case review and medical necessity determination for each Health Plan member. Copyright 2006 by Prescription Solutions. All rights reserved. This Prior Authorization Guideline is intended for use by Prescription Solutions and Health Plan employees and applicable contracted providers and practitioners only. The information contained in this Prior Authorization Guideline is confidential and proprietary to Prescription Solutions and shall not be used, reproduced, or transferred in whole or in part without Prescription Solutions prior written consent.

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

PRODUCT MONOGRAPH ALIMTA

PRODUCT MONOGRAPH ALIMTA PRODUCT MONOGRAPH Pr ALIMTA Pemetrexed Disodium for Injection 100 mg or 500 mg pemetrexed per vial Antineoplastic Agent Eli Lilly Canada Inc. 3650 Danforth Avenue Toronto, Ontario M1N 2E8 1-888-545-5972

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Alimta (pemetrexed) Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective

More information

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to

More information

BILLING AND CODING INFORMATION

BILLING AND CODING INFORMATION Effective April 1, 2016, C-Code for Portrazza: C9475, Injection, necitumumab, 1 mg BILLING AND CODING INFORMATION INDICATION Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist

More information

Drug Review Pemetrexed for Injection Alimta

Drug Review Pemetrexed for Injection Alimta Drug Review Pemetrexed for Injection Alimta Reviewer: Jamilah Al-Saedan B.Sc Pharm, King Saud University Introduction Malignant pleural mesothelioma A rare form of cancer. It is a malignant tumor of the

More information

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Report on New Patented Drugs - Alimta

Report on New Patented Drugs - Alimta Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive

More information

FULL PRESCRIBING INFORMATION: CONTENTS*

FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Gemcitabine for Injection, USP safely and effectively. See full prescribing information for Gemcitabine

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer

Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Thomas E. Stinchcombe, Mark A. Socinski Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

Strength of Study End Point(s): Progression-free survival

Strength of Study End Point(s): Progression-free survival AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and

More information

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group

REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore

Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore Original Article Singapore Med J 2011; 52(3) : 190 Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore Lopes G, Chopra A, Kukutschka J, Portillo P, Bharwani L,

More information

Management of Platinum-Sensitive Recurrent Ovarian Cancer

Management of Platinum-Sensitive Recurrent Ovarian Cancer Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

SECOND-LINE CHEMOTHERAPY in advanced non

SECOND-LINE CHEMOTHERAPY in advanced non Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,

More information

Redacted Protocol for Journal of Clinical Oncology

Redacted Protocol for Journal of Clinical Oncology Redacted PARAMOUNT Clinical Protocol Page 1 Redacted Protocol for Journal of Clinical Oncology Protocol S124(b) (PARAMOUNT) A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance plus Best Supportive

More information

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab. Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

How valuable is a cancer therapy? It depends on who you ask.

How valuable is a cancer therapy? It depends on who you ask. How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Cancer Treatment Reviews

Cancer Treatment Reviews Cancer Treatment Reviews 35 (2009) 364 373 Contents lists available at ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT Pemetrexed in

More information

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. 1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:

More information

Regimen: Gemcitabine & Carboplatin for NSCLC

Regimen: Gemcitabine & Carboplatin for NSCLC Regimen: Gemcitabine & Carboplatin for NSCLC ICD10 codes Codes pre-fixed with C34. Indications Regimen details First-line chemotherapy for advanced (stage IIIB/IV) non-small cell lung cancer (NICE CG121)

More information

5.04.20. Perjeta. Perjeta (pertuzumab) Description

5.04.20. Perjeta. Perjeta (pertuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)

More information

Clinical Trials for Patients with

Clinical Trials for Patients with Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee

More information

DECISION AID SET. STAGE IV Non-Small Cell Lung Cancer (NSCLC)

DECISION AID SET. STAGE IV Non-Small Cell Lung Cancer (NSCLC) DECISION AID SET STAGE IV Non-Small Cell Lung Cancer (NSCLC) Dear Clinician: This set of DECISION AIDS is based on ASCO s Clinical Practice Guideline Update on Chemotherapy for Stage IV NSCLC (2009). ASCO

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Treatment Paradigm in NSCLC Treatment

Treatment Paradigm in NSCLC Treatment Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status

More information

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen

More information

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN

Hospital Outpatient Coding and Billing Information Sheet for Neulasta and NEUPOGEN Hospital Outpatient Coding and Billing Information Sheet for Neulasta and Neulasta Delivery Kit Neulasta Prefilled Syringe For assistance contact 1-844-MYNEULASTA (1-844-696-3852) or visit www.amgenassistonline.com

More information

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

Gemcitabine and Cisplatin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer: Results of a Phase II Trial

Gemcitabine and Cisplatin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer: Results of a Phase II Trial Gemcitabine and Cisplatin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer: Results of a Phase II Trial Mouhammed J Kyasa, MD Randall L Breau, MD Ehab Hanna, MD James Suen,

More information

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?

Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? 4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology. Endorsement of the American College of Chest Physicians (ACCP) Guideline

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology. Endorsement of the American College of Chest Physicians (ACCP) Guideline Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Table of Contents Data Supplement 1: Summary of included

More information

Pemetrexed for the maintenance treatment of non-small-cell lung cancer

Pemetrexed for the maintenance treatment of non-small-cell lung cancer Pemetrexed for the maintenance treatment of non-small-cell lung cancer Issued: June 2010 guidance.nice.org.uk/ta190 NICE has accredited the process used by the Centre for Health Technology Evaluation at

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ALIMTA 500 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains

More information